Ulisse Biomed becomes Helyx Industries S.p.A. and strengthens its architecture: Hyris for the integrated qPCR platform and OEM services, Vytro for IVD-certified PCR solutions for hospitals and laboratories, and Mytho for customised NGS.
Helyx Industries S.p.A. is the new name for Ulisse Biomed: a change that clarifies the company's evolution and the scale of the industrial project built up over recent years. The rebranding has a specific objective: to coherently represent an integrated group in the field of genetics, with proprietary expertise and technologies covering the entire molecular biology value chain, from PCR to deep multiplexing and next-generation sequencing (NGS).
Within this framework, the new brand is accompanied by a clearer and more focused organisational structure. Helyx Industries now operates through three divisions, each with a defined scope, a dedicated market language and a targeted value proposition. The logic is simple: to maintain a unified industrial vision, but with specialised operational lines to respond precisely to the needs of different sectors and stakeholders.
HYRIS – Proprietary platform and integrated services
Hyris is the division that brings together products and services developed around Hyris System™, a proprietary technology platform that integrates hardware, software and reagents. This is where solutions for qPCR in distributed environments are developed and delivered, together with ready-made products for areas such as agrifood and nutraceuticals. The division also oversees OEM services with dual ISO 9001 and ISO 13485 certification, as well as end-to-end development: from bioinformatics to panel design and production. The platform's distinctive features, such as ambient-stable reagents and the bAPP™ cloud component, designed to enable operational flexibility and continuity of use in real-world scenarios, complete the offering.
VYTRO – PCR solutions for hospitals and laboratories, with IVD certification
Vytro is the Division focused on the clinical and medical world. It brings to market a catalogue of IVD-certified PCR products and solutions designed for hospitals, clinical laboratories and diagnostic centres. Its positioning is based on distinctive and innovative kits for high-impact applications (including HPV, STDs, respiratory diseases, oncohematology and pharmacogenetics), as well as proprietary kits for DNA/RNA extraction. Vytro also features proprietary deep multiplexing technologies, which further strengthen its diagnostic offering. The approach is that of a complete solution for molecular biology, built to integrate performance, reliability and compliance requirements, while maintaining technological consistency with the group's platform.
MYTHO – Custom NGS and highly specialised services
Mytho is the group's NGS pillar. The division operates exclusively in next-generation sequencing and focuses on highly customised projects: tailor-made NGS panels, super-customisation based on the needs of the geneticist and the laboratory, and full compatibility with the main instrumental technologies. At this stage, Mytho does not offer “off-the-shelf” IVD solutions: its approach is consultative and specialised, built around data quality and the transformation of genomic information into useful insights. It is in this area that Helyx is consolidating its presence in the fields of advanced genomics and precision medicine, with applications including molecular oncology, rare diseases and infectious diseases.
The rebranding to Helyx Industries and the redefinition of the Divisions are therefore two elements of the same process: making an integrated industrial strategy more readable, but capable of speaking precisely to different markets. A new identity, a clearer organisation and three complementary Divisions: the basis for continuing to develop solutions and services throughout the molecular biology value chain.
_____
For an in-depth look: Insights
Press Release: Downlaod PDF
